In 2021, the C + I vaccine was proven to stimulate cytotoxic anti-tumor CD8 T cell effector and memory responses, induce cancer-specific humoral immune responses, reduce immunosuppressive CD4 T regulatory cells, and prevent tumor formation in 75% of PDAC mice [147]. The gene discussed is CD8A; the disease is neoplasm.